Sign In
27 May 2011 09:24

For immediate release | 27 May 2011 |
ABCAM PLC
("Abcam" or "the Company")
Additional Listing
Â
Application has been made to AIM for the admission of 279,521 ordinary shares of 0.2p each in the Company to trading. These shares, which will rank pari passu in all respects with the existing shares in issue, have been allotted following the Company's acquisition of MitoSciences Inc. announced on 24 May 2011. Settlement of this transaction is by way of a cash consideration of US$4.2 million (ÂŁ2.6 million) and US$1.8 million (ÂŁ1.1 million) of Abcam shares issued at 397.1p being the rolling five day average price terminating three days prior to completion. Admission is expected to become effective on 1 June 2011.
Â
Â
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser | |
James Black - Corporate Broking | |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Â
Â
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality research-grade antibodies and associated proteomics research products. Antibodies and related products are essential tools for life scientists enabling them to analyse components of living cells at the molecular level.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Cambridge, Massachusetts (USA), Tokyo (Japan) and Hong Kong (China) allowing them to serve a global customer base of 75 countries. Abcam employs over 290 staff across its four operating companies.
Abcam now has an online catalogue of over 72,000 products sourced from over 250 suppliers. The catalogue includes a growing range of non-antibody products such as proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed e-commerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research and detection tools globally.
Follow the stocks
